Source comparison
PT-141 Research Applications: Comparison Table
Female Hypoactive Sexual Desire Disorder MC4R activation in hypothalamic arousal centers increases sexual motivation independent of estrogen signaling 1.75mg subcutaneous 45 min pre-activity 24-week trials standard; single-dose studies measure acute response F
This comparison does not assign a generated winner or score.
- Female Hypoactive Sexual Desire Disorder
- MC4R activation in hypothalamic arousal centers increases sexual motivation independent of estrogen signaling
- 1.75mg subcutaneous 45 min pre-activity
- 24-week trials standard; single-dose studies measure acute response
- FDA-approved for this indication; RECONNECT trials showed 25% 'much improved' vs 17% placebo. Modest but statistically significant effect
- Male Psychogenic Erectile Dysfunction
- Central arousal pathway activation bypasses need for peripheral nitric oxide signaling that PDE5 inhibitors require
- 1.25–2mg subcutaneous; intranasal route studied at higher doses before discontinuation
- 8–12 week protocols typical
- Most effective in men who fail PDE5 inhibitors; works through different pathway so combination therapy possible but unstudied
- SSRI-Induced Sexual Dysfunction
- Melanocortin receptor activation counteracts serotonergic suppression of dopamine release in sexual arousal circuits
- 1–1.75mg subcutaneous; often studied as adjunct to ongoing SSRI therapy
- 12-week minimum to separate from antidepressant dose adjustments
- Promising early data; addresses a treatment gap where dose reduction and drug holidays have limited efficacy
- Post-Menopausal Female Sexual Arousal Disorder
- MC4R pathway functions independently of estrogen; activates arousal response without requiring HRT
- 1.75mg subcutaneous standard; some protocols test 2.5mg
- 16–24 week studies
- Not FDA-approved for this population yet; trials ongoing but early data shows similar response rates to premenopausal HSDD
- Neurological Conditions (Spinal Cord Injury, MS)
- Central pathway activation may bypass damaged peripheral nerves; arousal initiated at hypothalamic level
- 2–3mg doses studied; higher than cosmetic use due to reduced receptor sensitivity in some neurological conditions
- 6–12 months; longer observation periods needed
- Highly experimental; case series suggest benefit but no large controlled trials published
- The table above demonstrates PT-141's research versatility across sexual dysfunction subtypes that share a common feature: central arousal pathway impairment that peripheral vascular treatments don't address. The melanocortin mechanism offers an alternative when traditional therapies fail, but the relatively modest effect sizes (8–10% absolute improvement over placebo in most trials) mean it's not a universal solution. It works best in populations where desire and arousal. Not physical genital response. Are the primary deficits.